Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion.

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

However, recent efficacy and side effect concerns over Novo Nordisk's pipeline candidate Monlunabant have likely worsened NVO's recent buying sentiments as investors reassessed future growth ...